In the early setting, there is still a considerable number of relapses, and, in the metastatic setting, most cases eventually progress under HER-2-targeted therapy, due to either suboptimal tumor cell growth inhibition or mechanisms of resistance. This evidence concerns the gene ERBB2 and neoplasm.